Allergy Immunotherapies Market Report by Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy ), Allergy Type, Distribution Channel, and Region 2025-2033
The global allergy immunotherapies market size reached USD 3.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.5 Billion by 2033, exhibiting a growth rate (CAGR) of 8.29% during 2025-2033. The market is propelled by the rising prevalence of allergic conditions, increasing awareness about immunotherapy as an effective treatment for allergies, significant developments in immunotherapy treatments and technologies, favorable government policies and funding for allergy research, and customized medicine and tailored treatment approaches.
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system's response by gradually increasing the doses of the allergen. Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient's life.
In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world. Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.
Key Market Segmentation:
Breakup by Treatment Type:
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
Breakup by Allergy Type:
Allergic Rhinitis
Asthma
Food Allergy
Venom Allergy
Others
Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Breakup by Region:
Europe
North America
Asia Pacific
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, etc.
Key Questions Answered in This Report
1.What was the size of the global allergy immunotherapies market in 2024?
2.What is the expected growth rate of the global allergy immunotherapies market during 2025-2033?
3.What are the key factors driving the global allergy immunotherapies market?
4.What has been the impact of COVID-19 on the global allergy immunotherapies market?
5.What is the breakup of the global allergy immunotherapies market based on the treatment type?
6.What is the breakup of the global allergy immunotherapies market based on the allergy type?
7.What is the breakup of the global allergy immunotherapies market based on the distribution channel?
8.What are the key regions in the global allergy immunotherapies market?
9.Who are the key players/companies in the global allergy immunotherapies market?